IDH1/2 inhibitors for AML

Panelists Elias Jabbour, MD; Martin S. Tallman, MD; Richard M. Stone, MD; Harry P. Erba, MD, PhD; and Mark J. Levis, MD, PhD, outline targeting other mutations in acute myeloid leukemia and the use of IDH1 and IDH2 inhibitors.